Linzagolix
| |
| |
Clinical data | |
---|---|
Synonyms | KLH-2109; OBE-2109 |
Routes of administration | By mouth[1][2] |
Drug class | GnRH modulator; GnRH antagonist; Antigonadotropin |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H15F3N2O7S |
Molar mass | 508.424 g/mol |
3D model (JSmol) | |
| |
|
Linzagolix (INN; developmental code names KLH-2109, OBE-2109) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.[1][3][2] As of December 2017, it is in phase III clinical trials for uterine fibroids and phase II clinical studies for endometriosis and adenomyosis.[1]
See also
References
- 1 2 3 http://adisinsight.springer.com/drugs/800032710
- 1 2 Ezzati M, Carr BR (2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Womens Health (Lond). 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.
- ↑ Chodankar, Rohan; Allison, Jennifer (2018). "New Horizons in Fibroid Management". Current Obstetrics and Gynecology Reports. 7 (2): 106–115. doi:10.1007/s13669-018-0242-6. ISSN 2161-3303.
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.